# Centrally Acting ACE Inhibition in SLE

> **NCT04486118** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Northwell Health** · enrollment: 36 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Lisinopril Pills
- **DRUG:** Benazepril Pill

## Key facts

- **NCT ID:** NCT04486118
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-01
- **Primary completion:** 2025-06-03
- **Final completion:** 2026-03-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486118, "Centrally Acting ACE Inhibition in SLE". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04486118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*